1-[(benzyloxy)carbonyl]-2-methylazetidine-2-carboxylic acid | 912335-92-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(benzyloxy)carbonyl]-2-methylazetidine-2-carboxylic acid
• 英文别名: 1-((Benzyloxy)carbonyl)-2-methylazetidine-2-carboxylic acid；2-methyl-1-phenylmethoxycarbonylazetidine-2-carboxylic acid
• CAS: 912335-92-3
• 化学式: C₁₃H₁₅NO₄
• 分子量: 249.266
• InChiKey: KVJTUZMRAXZYDZ-UHFFFAOYSA-N

物化性质

• 沸点：
  414.9±45.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[(benzyloxy)carbonyl]-2-methylazetidine-2-carboxylic acid 、 L-丙氨酸甲酯盐酸盐 在 TEA 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以89%的产率得到benzyl 2-[[(2S)-1-methoxy-1-oxopropan-2-yl]carbamoyl]-2-methylazetidine-1-carboxylate
  参考文献：
  名称：

  Azetidine-Derived Amino Acids versus Proline Derivatives. Alternative Trends in Reverse Turn Induction

  摘要：

  [Graphics]The influence of 2-alkyl-2-carboxyazetidines (Aze) on the 3D structure of model tetrapeptides (RCO)-C-2-2-R(1)Aze-L-Ala-NHMe has been analyzed by molecular modeling, H-1 NMR, and FT-IR studies. The conformational constraints introduced by the four-membered ring resulted in an effective way to stabilize gamma-turn-like conformations in these short peptides. The conformational preferences of these Aze-containing peptides have been compared to those of the corresponding peptide analogues containing Pro or a-MePro in the place of 2-alkyl-Aze residue. In the model studied, both Pro and Aze derivatives are able to induce reverse turns, but the nature of the turn is different as a function of the ring size. While the five-membered ring of Pro tends to induce beta-turns, as previously suggested by different authors, the four-membered ring of Aze residues forces the peptide to preferentially adopt gamma-turn conformations. In both cases, the presence of an alkyl group at the alpha-position of Pro or the azetidine-2-carboxylate ring enhances significantly the turn-inducing ability. These results might open the opportunity of using 2-alkyl-Aze residues as versatile tools in defining the role of gamma-turn structures within the bioactive conformation of selected peptides, and represent an alternative to Pro derivatives as turn inducers.

  DOI：

  10.1021/jo701746w
• 作为产物：
  描述：

  1-O-benzyl 2-O-methyl 2-methylazetidine-1,2-dicarboxylate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以92%的产率得到1-[(benzyloxy)carbonyl]-2-methylazetidine-2-carboxylic acid
  参考文献：
  名称：

  Azetidine-Derived Amino Acids versus Proline Derivatives. Alternative Trends in Reverse Turn Induction

  摘要：

  [Graphics]The influence of 2-alkyl-2-carboxyazetidines (Aze) on the 3D structure of model tetrapeptides (RCO)-C-2-2-R(1)Aze-L-Ala-NHMe has been analyzed by molecular modeling, H-1 NMR, and FT-IR studies. The conformational constraints introduced by the four-membered ring resulted in an effective way to stabilize gamma-turn-like conformations in these short peptides. The conformational preferences of these Aze-containing peptides have been compared to those of the corresponding peptide analogues containing Pro or a-MePro in the place of 2-alkyl-Aze residue. In the model studied, both Pro and Aze derivatives are able to induce reverse turns, but the nature of the turn is different as a function of the ring size. While the five-membered ring of Pro tends to induce beta-turns, as previously suggested by different authors, the four-membered ring of Aze residues forces the peptide to preferentially adopt gamma-turn conformations. In both cases, the presence of an alkyl group at the alpha-position of Pro or the azetidine-2-carboxylate ring enhances significantly the turn-inducing ability. These results might open the opportunity of using 2-alkyl-Aze residues as versatile tools in defining the role of gamma-turn structures within the bioactive conformation of selected peptides, and represent an alternative to Pro derivatives as turn inducers.

  DOI：

  10.1021/jo701746w

文献信息

• 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
  申请人：Zhu Gui-Dong

  公开号：US20060229289A1

  公开（公告）日：2006-10-12

  Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

  公式(I)的化合物抑制PARP酶，并且对于治疗与PARP相关的疾病或障碍是有用的。还披露了包括公式(I)化合物的药物组合物、包括公式(I)化合物的治疗方法，以及包括公式(I)化合物的抑制PARP酶的方法。
• 2-Substituted-1 H-benzimidazile-4-carboxamides are PARP inhibitors
  申请人：Zhu Gui-Dong

  公开号：US20060229351A1

  公开（公告）日：2006-10-12

  Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), method of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compound of Formula (I).

  公式（I）的化合物抑制PARP酶，可用于治疗与PARP相关的疾病或紊乱。还披露了包括公式（I）化合物的药物组合物、包括公式（I）化合物的治疗方法，以及包括公式（I）化合物的抑制PARP酶的方法。
• 2-SUBSTITUTED-1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE PARP INHIBITORS
  申请人：Zhu Gui-Dong

  公开号：US20100234425A1

  公开（公告）日：2010-09-16

  Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

  公式（I）的化合物能够抑制PARP酶，适用于治疗与PARP相关的疾病或疾病。还披露了包括公式（I）化合物的药物组合物，包括公式（I）化合物的治疗方法，以及包括公式（I）化合物的PARP酶抑制方法。
• 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer
  申请人：Abbott Laboratories

  公开号：EP2420234A1

  公开（公告）日：2012-02-22

  Compounds of Formula (I) (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

  式(I)(I)化合物抑制PARP酶，可用于治疗与PARP相关的疾病或紊乱。还公开了包含式（I）化合物的药物组合物、包含式（I）化合物的治疗方法以及包含式（I）化合物的抑制 PARP 酶的方法。
• 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors
  申请人：Abbott Laboratories

  公开号：EP2420499A1

  公开（公告）日：2012-02-22

  Compounds of Formula (I) (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

  式(I)(I)化合物抑制PARP酶，可用于治疗与PARP相关的疾病或紊乱。还公开了包含式（I）化合物的药物组合物、包含式（I）化合物的治疗方法以及包含式（I）化合物的抑制 PARP 酶的方法。